Evommune (NYSE:EVMN – Get Free Report) released its quarterly earnings data on Thursday. The company reported ($8.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($6.58) by ($1.49), Zacks reports.
Evommune Price Performance
Evommune stock traded up $0.17 during trading hours on Thursday, hitting $19.78. The company had a trading volume of 264,683 shares, compared to its average volume of 109,103. Evommune has a 1 year low of $16.70 and a 1 year high of $24.03.
Wall Street Analyst Weigh In
Several equities research analysts recently weighed in on the stock. Leerink Partners began coverage on shares of Evommune in a research report on Monday, December 1st. They issued an “outperform” rating and a $42.00 price target on the stock. Zacks Research upgraded shares of Evommune to a “hold” rating in a report on Tuesday, December 2nd. Leerink Partnrs upgraded shares of Evommune to a “strong-buy” rating in a research report on Monday, December 1st. Morgan Stanley initiated coverage on Evommune in a research report on Monday, December 1st. They issued an “overweight” rating and a $36.00 price target for the company. Finally, Cantor Fitzgerald began coverage on Evommune in a research note on Monday, December 1st. They set an “overweight” rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $39.33.
About Evommune
Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions.
Further Reading
- Five stocks we like better than Evommune
- What is the Nikkei 225 index?
- Beyond the Magnificent 7: Meet 3 of Tech’s Rising Stars
- Differences Between Momentum Investing and Long Term Investing
- The Quantum Fleet: Investing in the New Quantum Standard
- Pets Are Big Business: 4 Big-Ticket Pet Stocks to Add to Your Portfolio
- AST SpaceMobile Gears Up for Its BlueBird 6 Launch Next Week
Receive News & Ratings for Evommune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evommune and related companies with MarketBeat.com's FREE daily email newsletter.
